Zacks Investment Research downgraded shares of MEDIDATA SOLUTN (MDSO) from OUTPERFORM to NEUTRAL on September 24, 2013, with a target price of $104.70.
Medidata Solutions is a leading global provider of hosted clinical development solutions that enhance the efficiency of customers' clinical development processes and optimize their research and development investments. Medidata products and services allow customers to achieve clinical results more efficiently and effectively by streamlining the design, planning and management of key aspects of the clinical development process, including protocol development (Medidata Designer), investigator benchmarking and budgeting (Medidata Grants Manager), contract research organization (CRO) benchmarking and budgeting (Medidata CRO Contractor), and the capture, management, analysis and reporting of clinical trial data (Medidata Rave). Medidata's diverse customer base spans pharmaceutical, biotechnology and medical device companies, academic institutions, CROs and other research organizations, and includes some top global pharmaceutical companies.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on MEDIDATA SOLUTN (MDSO),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment